Each week, our Regional Roundup delivers the most important and timely life sciences news from around the region. From groundbreaking research to fundraising, new development projects, and who’s hiring — we bring you the top stories that matter most. Stay informed with a curated selection of the latest news, delivered directly to your inbox weekly.
Two weeks ago, Greater Philadelphia was hedging its bets and waiting for proof before committing. This week, the commitments came first. Across the send, pharma partners, federal funders and the region’s own talent builders made real commitments before the point where it usually feels safe to: before a first patient, before first symptoms, before a launch, and a full year before the interns show up.
The biggest checks went to the earliest science. Merck agreed to pay up to $2.13 billion, $400 million of it upfront, for a KRAS inhibitor that hasn’t been tested in a single patient. Genentech signed a deal worth more than $1.5 billion with Earendil Labs to discover bispecific antibodies that don’t exist yet. Penn and the University of Miami landed $26 million from the NIH to catch ALS and FTD before symptoms ever appear, laying the groundwork for prevention trials that could act before irreversible damage sets in.
The people side is moving early too. Larimar brought on John Harlow, who has built commercial teams from scratch before, as President and COO ahead of a potential launch for its Friedreich’s ataxia therapy. Life Science Cares Philadelphia is already asking companies to pledge paid 2027 internships through “Fill the Map,” so a student’s shot at the industry doesn’t depend on a 90-minute commute.
Minaris is getting ahead of the in vivo gene therapy market by carving out a dedicated Viral Vectors unit, and it’s hiring for 90+ roles across the region right now.
Financial
Tracking the capital moving through Greater Philadelphia— funding rounds, M&A activity, and investment trends shaping Philadelphia, Southern New Jersey, and Delaware’s life sciences companies.
Why Big Pharma Is Paying Big for Antibodies That Hit Cancer From Two Sides
Earendil Labs has landed a deal worth more than $1.5 billion with Genentech to hunt down a new generation of cancer antibodies, molecules designed to hit tumors from two angles at once instead of one. It’s the AI-driven biotech’s second major pharma partnership this year, following deals with Sanofi that already put its platform on the map. Here’s what makes bispecific antibodies different, and why Big Pharma keeps coming back. Read More >
What If ALS and FTD Could Be Stopped Before They Begin?
Penn and the University of Miami have landed $26 million from the NIH to chase something that’s eluded ALS and FTD treatment for years: a way to spot the disease before symptoms ever appear. The five-year study targets a specific genetic variant behind both conditions, building toward prevention trials that could intervene before irreversible damage sets in. Here’s what the funding is actually going toward. Read More >
DARPA Just Bet $11 Million on Treating Depression in a Single Day
NRx Pharmaceuticals has landed a major DARPA contract to test whether a single-day treatment, combining robotic brain stimulation with its depression drug, can outperform the weeks-long regimens used today. Early data already points to a striking response rate, one that could reshape treatment for people who can’t wait weeks for relief. Here’s how the approach actually works. Read More >
People
Who we’re buzzing about this week — the leadership moves, board appointments, and rising names shaping the region’s life sciences community.
Why a 25-Year Biotech Veteran Just Bet on Aro’s “Hard to Reach” Platform
Brett Blackman, who helped build Valo Health from its founding through today as COO, is bringing that experience to Aro Biotherapeutics’ board, a Philadelphia biotech targeting tissues that have long been hard to reach. He’s no stranger to turning early science into real companies. Here’s what drew him to Aro, and what he’ll help steer next. Read More >
This Exec Helped Turn Around One Biotech — Now He’s Prepping Another for Launch
John Harlow is joining Larimar Therapeutics as President and COO at a pivotal moment, as the company inches toward a potential launch for its lead therapy in Friedreich’s ataxia. He’s built commercial teams from scratch before, including leading Melinta Therapeutics through a turnaround that ended in an acquisition. Here’s what he’ll be building at Larimar, and why the timing lines up with his track record. Read More >
This Exec Guided 12 Drug Launches at BMS — Now He’s Joining a Cell Therapy Leader
Josh Schwartz is joining Legend Biotech as Senior Vice President, bringing over a decade of medical affairs leadership from BeOne Medicines, TG Therapeutics, and Bristol Myers Squibb, including guiding field teams through a dozen drug launches at BMS. He’ll help steer Legend’s cell therapy portfolio as it grows beyond its flagship CAR-T therapy. Read More >
Why a Digital Medicine Strategist Just Jumped From Oncology to Respiratory
Tyler Reynolds is joining GSK as Director, Digital Medicine after three years shaping digital strategy in oncology and cell therapy at AstraZeneca and its health-tech spinout, Evinova. Now he’s bringing that playbook to respiratory, immunology, and inflammation, one of GSK’s core therapeutic areas. Read More >
Workforce
The hiring activity, team expansions, and talent trends driving growth across Philadelphia, New Jersey, and Delaware life sciences and biotech employers.
Life Science Cares Philadelphia Wants Your Company on the Map
For one Project Onramp intern, a paid internship still meant a 6 AM start, an hour and a half of transit, and $20 a day just to get to work. Life Science Cares Philadelphia is launching “Fill the Map,” a 2027 push to recruit host companies across the whole region so opportunity doesn’t depend on a student’s commute — and Mitovon Biosciences just planted the first pin. Can your company pledge a paid 2027 internship and add its pin to the map? Read More >
Penn’s Life Sciences Talent Pipeline Just Got a New Consulting Connection
Penn Biotech Group brought Windrose Consulting Group in for a recruiting session that drew over 25 graduate students and postdocs curious about life sciences consulting careers, and the conversation ran so long past the scheduled end time that organizers extended it. Here’s what students learned about breaking into the field, and how companies can get involved next. Read More >
Who’s hiring?!
Top Employer
A global contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, Minaris Advanced Therapies is dedicated to helping innovators succeed, from early-stage development through commercial launch , with end-to-end expertise in GMP manufacturing, biosafety, and analytical testing of biologics.
With a state-of-the-art manufacturing facility in the Greater Philadelphia region, Minaris is strengthening one of the world’s leading cell and gene therapy hubs by bringing together scientists, engineers, quality experts, and problem solvers dedicated to helping life-changing therapies reach patients faster and more reliably.
They are currently hiring across 90+ roles in the Greater Philadelphia region. Apply Now >
Other employers and available roles we’re paying attention to this week:
- Merck (North Wales, PA & Rahway, NJ) is hiring a Principal Scientist, Biostatistics, Clinical Safety Statistics | Apply Now >
- Incyte (Wilmington, DE) is hiring a Manager, Microsoft Cloud Service | Apply Now >
- AbbVie (Wilmington, DE) is hiring a Senior Director, Clinical Supply Release | Apply Now >
- ICON plc (Bluebell, PA) is hiring a Global Trial Optimization Specialist | Apply Now >
- Johnson & Johnson (Spring House, PA) is hiring a Post Doc, R&D Immunology – Population Analytics & Insights | Apply Now >
Clinical + Commercial
The latest clinical trial progress, regulatory milestones, and commercial launches from companies advancing science from the lab to the market across Greater Philadelphia.
The Organ Behind Your Immune System Is Getting Serious Biotech Attention
Tolerance Bio has struck its second clinical-stage licensing deal in under six weeks, bringing in a Tanabe Pharma antibody already tested in over 150 patients to protect the organ behind our immune system as it declines with age. Paired with an earlier deal to restore that same organ, the company says it now has the broadest thymus-focused pipeline in the field. Read More >
Merck Is Paying Billions for a Drug That Hasn’t Been Tested on a Single Patient
Merck has struck a deal worth up to $2.13 billion for a still-preclinical drug candidate designed to hit one of cancer’s most stubborn targets, the KRAS mutation behind a huge share of pancreatic, colorectal, and lung cancers. The $400 million upfront payment goes to a Shanghai biotech founded just two years ago. Here’s why Merck is betting big on a molecule that hasn’t even entered human trials yet. Read More >
From Classrooms to Labs: A New Cloud Tool Wants to Democratize Chemical Drawing
Certara has launched Marvin Cloud, putting professional-grade chemical structure drawing tools in a browser, no institutional software required. The platform brings publication-ready sketching, stereochemistry handling, and property calculations to independent scientists, teachers, and students who’ve previously needed a lab’s full software stack to access them. Here’s what’s inside, and how to try it free for 14 days. Read More >
This AI Assistant Could Cut Clinical Trial Setup Time by 80%
Suvoda has unified eight separate clinical trial tools, from randomization to patient payments, into a single platform with one login, aiming to end the login-juggling that’s long slowed down trial sites. The release also introduces an AI assistant that can cut study kickoff timelines by up to 80%. Here’s how the unified approach actually works for sites and patients. Read More >
Ecosystem
The partnerships, programs, and policy moves building Greater Philadelphia’s life sciences infrastructure — and the organizations driving it forward.
This CDMO Just Carved Out a Business Unit for One of Gene Therapy’s Hottest Niches
Minaris is splitting itself into three specialized divisions, carving out a dedicated Viral Vectors unit to chase the fast-growing in vivo gene therapy market. The Philadelphia-based CDMO is betting that sharper focus, backed by decades of expertise in each division, will serve cell and gene therapy developers better than a single combined operation. Here’s who’s leading each new unit, and why now. Read More >
Essex County College’s New Center Is Betting on the Region’s Tech Future
Essex County College has opened a newly renovated Center for Technology in Newark, built with a $4 million state grant to give students hands-on access to 3D printers, modern computing, and other career-ready tech. For one computer science student, it’s “much more than a renovated building.” Here’s what’s inside, and how it fits the college’s bigger workforce push. Read More >
A New Partnership Is Changing the Game for AAV Manufacturing
Minaris and Asimov are joining forces to fix one of AAV manufacturing’s biggest bottlenecks: unstable, low-titer producer cell lines. The partnership pairs Minaris’ OXGENE tech with Asimov’s AAV Edge platform to build cell lines purpose-built for scale. Read More >
Other [Good] Reads
Editor’s picks from across the web — the stories, videos, and podcasts shaping the conversation in PHL biotech and life sciences this week.
Wistar Scientists Identify Connection Between Nervous System and Aggressive Prostate Cancer
Wistar scientists have found that an aggressive, treatment-resistant form of prostate cancer may be quietly talking to the nervous system, and blocking that conversation could restore the immune system’s ability to fight back. The discovery targets a specific molecule tumors use to keep immune cells at bay before cancer even fully develops. Here’s how researchers turned a “cold” tumor hot again. Read More >
Yuta Lee explain how CRISPR has turned gene editing from science fiction into a working tool i the One Thirty Labs podcast
Yuta Lee breaks down how CRISPR actually works on the One Thirty Labs podcast, turning what sounds like science fiction into a precise, programmable editing tool for human DNA. The explanation gets into why this approach is moving the needle specifically on diseases caused by a single faulty gene. Read More >
BriaCell in Focus: CEO Insights & What’s Coming Next
PABC CEO Lou Kassa sits down with BriaCell’s CEO on the latest episode of Biotech Insiders, digging into the company’s recent progress and what’s on the horizon. The conversation also teases PABC’s upcoming Regional Biotechnology Conference on October 15, featuring keynotes from heavyweights like former J&J chairman Alex Gorsky. Read More >
On the Calendar
A few of the upcoming events, conferences, and networking opportunities across Greater Philadelphia’s life sciences ecosystem that you don’t want to miss.
MedTech Validation & Innovation University 2026
Thursday, October 7-8, 2026 • 9:00 AM- 5:00 PM • Philadelphia, PA
Hosted by Kenx | Register Now >
Pennovation Works 10th Anniversary Reception
Thursday, October 8, 2026 • 4:30- 7:30 PM • Philadelphia, PA
Hosted by Pennovation Works | Register Now >
Life Sciences Dreamin’ 2026 Conference
Thursday, October 8, 2026 • 9:00 AM – 6:00 PM • Fort Washington, PA
Hosted by Cloud Adoption Solutions | Register Now >
Did we miss something!? Drop us a line →
Stay connected to Greater Philadelphia’s life sciences.
🔍 Explore companies → · 💼 Browse jobs → · 📅 See events → · 📰 Read more →
Get the Greater Philadelphia Region Roundup every Thursday.
The week’s most important life sciences news from PHL— delivered to your inbox.
